These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9555606)

  • 21. Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.
    Fanous A; Lindenmayer JP
    J Clin Psychopharmacol; 1999 Jun; 19(3):275-6. PubMed ID: 10350037
    [No Abstract]   [Full Text] [Related]  

  • 22. Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?
    Stahl SM
    J Clin Psychiatry; 1999 Jul; 60(7):425-6. PubMed ID: 10453794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of recent clinical studies with olanzapine.
    Tollefson GD; Kuntz AJ
    Br J Psychiatry Suppl; 1999; (37):30-5. PubMed ID: 10211139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
    Citrome L; Volavka J; Czobor P; Sheitman B; Lindenmayer JP; McEvoy J; Cooper TB; Chakos M; Lieberman JA
    Psychiatr Serv; 2001 Nov; 52(11):1510-4. PubMed ID: 11684748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
    Tollefson GD; Andersen SW; Tran PV
    Biol Psychiatry; 1999 Aug; 46(3):365-73. PubMed ID: 10435202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.
    Aubry JM; Simon AE; Bertschy G
    J Clin Psychiatry; 2000 Sep; 61(9):649-55. PubMed ID: 11030485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
    Kasper S; Hale A; Azorin JM; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
    [No Abstract]   [Full Text] [Related]  

  • 29. Olanzapine and risperidone.
    Love RC; Kelly DL
    Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
    [No Abstract]   [Full Text] [Related]  

  • 30. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
    Simpson MM; Goetz RR; Devlin MJ; Goetz SA; Walsh BT
    J Clin Psychiatry; 2001 Sep; 62(9):694-700. PubMed ID: 11681765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report.
    Lerner V; Chudakova B; Kravets S; Polyakova I
    Clin Neuropharmacol; 2000; 23(5):284-6. PubMed ID: 11154098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
    Basson BR; Kinon BJ; Taylor CC; Szymanski KA; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Apr; 62(4):231-8. PubMed ID: 11379836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluations of olanzapine and risperidone.
    Shaw JW
    Am J Health Syst Pharm; 2002 Jul; 59(14):1366-75. PubMed ID: 12132564
    [No Abstract]   [Full Text] [Related]  

  • 36. Adverse events related to olanzapine.
    Conley RR; Meltzer HY
    J Clin Psychiatry; 2000; 61 Suppl 8():26-9; discussion 30. PubMed ID: 10811240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
    David SR; Taylor CC; Kinon BJ; Breier A
    Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
    Zhao Z
    Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of risperidone and olanzapine on the indications for clozapine.
    Ganguli R; Brar JS
    Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of cost, dosage and clinical preference for risperidone and olanzapine.
    Rabinowitz J; Lichtenberg P; Kaplan Z
    Schizophr Res; 2000 Dec; 46(2-3):91-6. PubMed ID: 11120420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.